Colin Hill

CEO & Co-Founder, Aitia

Colin Hill is a leading voice in AI and precision medicine and brings impressive leadership experience in developing and commercializing AI solutions and discoveries in biopharmaceutical drug discovery and development and in managed care industries. He co-founded leading AI bio simulation company Aitia Bio in 2000, and has since served as CEO. In 2020 the company launched the world’s first Virtual Patients beginning in Multiple Myeloma and has since launched Virtual Patients in Prostate Cancer andAlzheimer’s Disease. Colin currently serves on the board of Centrexion Therapeutics, a biotech company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs.

Colin previously served on the boards of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company (acquired by Philips in 2021), and PPD Inc. (NASDAQ: PPD), a leading global contract research organization (acquired by Thermo in 2021), and was a founding member of the Board ofDirectors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014).

He was also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council. Colin was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.

He is a frequent speaker at national and international scientific and industry conferences and has appeared in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.

He graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from both McGill University and Cornell University.

Debates Featuring Colin Hill

Is the FDA Too Cautious?

With Colin Hill, Peter Lurie

June 23, 2023

During the COVID-19 pandemic, the Atlantic criticized the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio ran a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to move safe and effective drugs as quickly as possible to patients who need them, it also needs to maintain the diligence and rigor necessary to prevent…

Is the FDA Too Cautious?

With Colin Hill, Peter Lurie

June 23, 2023

Features

Topics

Upcoming debates

SUPPORT OPEN-MINDED DEBATE

Colin Hill

Debates Featuring Colin Hill

Is the FDA Too Cautious?

Is the FDA Too Cautious?

Be Curious. Be Open-Minded. Be Open to Debate.